will provide the doctoral candidate with direct experience of translational pharmacology and the evaluation of a clinical-stage therapeutic.
The doctoral candidate will:
- Define the effects of resomelagon on inflammatory arthritis, systemic immune responses and cardiovascular comorbidities.
- Identify immune-cell trafficking, macrophage-reprogramming and resolution mechanisms associated with therapeutic response.
- Develop biomarker and PK/PD-informed strategies that support translation of resolution pharmacology to patient benefit.
Training and research environment
Translational and clinical pharmacology; experimental arthritis and cardiovascular models; immune-cell trafficking; macrophage phenotyping; specialised pro-resolving mediator analysis; biomarker development; PK/PD concepts; and biotechnology drug-development strategy.
Candidate profile
A background in pharmacology, immunology, clinical science, biotechnology or translational medicine, with enthusiasm for drug development and evaluation of clinical-stage therapeutics.
Candidates of any nationality are welcome to apply. Applicants should hold, or expect to obtain by October 2026, a Master’s degree (or equivalent qualification) that permits doctoral enrolment at QMUL. Applicants must not already hold a doctoral degree, must be proficient in English, and must satisfy the MSCA mobility rule: they must not have resided or carried out their principal activity in the United Kingdom for more than 12 months in the 36 months immediately preceding recruitment.
Application information
For more information, please visit: https://harpnet.eu/recruitment/
For any queries related to the applications please contact: info@harpnet.eu
Funding Notes
This is a fully funded Doctoral Candidate position within HARPNET, a Marie Skłodowska-Curie Actions Doctoral Network. HARPNET brings together universities, hospitals and industry partners across Europe to advance Resolution Pharmacology: the science of actively switching off harmful inflammation and promoting tissue repair. The doctoral candidate will join an international cohort of 15 researchers and undertake interdisciplinary training, network activities and international secondments.
Funding includes an employment contract and the applicable MSCA living and mobility allowances; family allowances may apply where eligible. Candidates should submit one central HARPNET application and may rank up to three project choices.
